2J·

Pfizer Q2 2025 Earnings Beat Estimates

$PFE (+0,68 %)


• Revenue: $14.65B vs. $13.5B estimate

• Adjusted EPS: $0.78 vs. $0.58 estimate

• Full Year 2025 Guidance:

 • Adjusted EPS between $2.90 and $3.10 (previously $2.80–$3.00)

 • Revenue forecast remains $61.0B to $64.0B

• Reaffirms full-year revenue guidance of $61.0B to $64.0B (consensus $62.57B)

• Raises full-year adjusted diluted EPS guidance by $0.10 to $2.90–$3.10 (consensus $3.01), including a one-time ~$0.20 impact from 3SBio transaction

• On track to deliver ~$7.2B in net cost savings by end of 2027 from cost improvement initiatives, supporting productivity gains and operating margin expansion

4
Participez à la conversation